The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed new measures to avoid exposure of babies to valproate medicines in the womb, because exposed babies are at high risk of malformations and developmental problems. The new measures include a ban on the use of such medicines for migraine or bipolar […]
New measures to avoid valproate exposure in pregnancy Read More »
Our General Assembly [GA] and the 1 st Migraine and Headache International Patient Advocacy Summit [MHIPAS], which will be held between Thursday, May 10 th and Sunday, May 13 th , at the NH Schiphol Airport Hotel, Amsterdam, Netherlands.
Migraine and Headache International patient Advocacy Summit (MHIPAS) Read More »
CHAD organised together with the EMHA Cluster Headache Special Interest Group [CHSIG], which will be held on March 21st in Paris. The draft programme is attached. The theme for this year will be “ Shaping a painless future for Cluster Headache”. During the event different important topics regarding CH will be discussed such as personal
Cluster Headache Awareness Day 2018 ( CHAD ) Read More »
The European Medicines Agency’s experts in medicines safety, the Pharmacovigilance Risk Assessment Committee (PRAC) are recommending new measures to avoid exposure of babies to valproate medicines in the womb. Babies exposed are at risk of malformations and developmental problems. The PRAC examined the available evidence and consulted widely with healthcare professionals and with patients, including women
PRAC recommends new measures to avoid valproate exposure in pregnancy Read More »
Exploratory Research into effect of Migraine in the workplace : This research develops on existing information, providing a deeper and wider spectrum of understanding into the effect of migraines. Reasons why employees choose to be present or absent, how triggers and symptoms can be managed, perceived human capital value, and possible spill overs from the
Migraine in the workplace: research Read More »
Brain Awareness Week 2018 (EBC): Expanding brain research in Europe – Education, Behaviour and Brain Development On 15 March 2018, EBC held its annual Brain Awareness Week event at the European Parliament (in Strasbourg, France) in partnership with FENS, EDAB, BBC, University of Strasbourg-Neuropole and the Bureau Grand Est. The event is designed for outreach to the general public and policymakers, to give
Brain Awareness Week- EBC Read More »
As we all have suffered once in our life from a “headache”, it is common to think that headache and migraine, are more or less, the same, and together we have reached the vulgarization of this disease that generates a true social misunderstanding of migreneurs. Now, what would you think of a disease that affects
People with migraine spend 2 years of their life in bed Read More »
On the 24 of January 2018, from 10.00 to 12:00, will be celebrated inside the European Parliament (Room ASP A3F383) a meeting focused on: “Making Visible The Invisible On Headache Pain: Sharing Successful Experiences Across Europe”. Register here for the 24 of January 2018. The initiative is promoted by Active Citizenship Network in partnership with the European Headache Alliance (EMHA), and it will
Making Visible The Invisible On Headache Pain Read More »
Laboratory-made antibody Erenumab blocks neural brain pathway and is first new treatment for attacks approved in 20 years A new migraine drug that can halve the length of time sufferers are laid low by the debilitating condition has been hailed as an “incredibly important” advance. Erenumab, a laboratory-made antibody that blocks a neural brain pathway
New Migraine drug hailed as “Incredibly important” breakthrough Read More »
Don't miss out on any updates! Join our community and discover
the latest research, treatments, and events on migraine.
Subscribe now!
